Please use this identifier to cite or link to this item: https://observatorio.fm.usp.br/handle/OPI/33482
Full metadata record
DC FieldValueLanguage
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorRAMOS, Marcus Fernando Kodama Pertille
dc.contributor.authorPEREIRA, Marina Alessandra
dc.contributor.authorCHARRUF, Amir Zeide
dc.contributor.authorDIAS, Andre Roncon
dc.contributor.authorCASTRIA, Tiago Biachi de
dc.contributor.authorBARCHI, Leandro Cardoso
dc.contributor.authorRIBEIRO-JUNIOR, Ulysses
dc.contributor.authorZILBERSTEIN, Bruno
dc.contributor.authorCECCONELLO, Ivan
dc.date.accessioned2019-09-23T14:18:06Z-
dc.date.available2019-09-23T14:18:06Z-
dc.date.issued2019
dc.identifier.citationABCD-ARQUIVOS BRASILEIROS DE CIRURGIA DIGESTIVA-BRAZILIAN ARCHIVES OF DIGESTIVE SURGERY, v.32, n.2, article ID UNSP e1435, 5p, 2019
dc.identifier.issn0102-6720
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/33482-
dc.description.abstractBackground: Conversion therapy in gastric cancer (GC) is defined as the use of chemotherapy/radiotherapy followed by surgical resection with curative intent of a tumor that was prior considered unresectable or oncologically incurable. Aim: To evaluate the results of conversion therapy in the treatment of GC. Methods: Retrospective analysis of all GC surgeries between 2009 and 2018. Patients who received any therapy before surgery were further identified to define the conversion group. Results: Out of 1003 surgeries performed for GC, 113 cases underwent neoadjuvant treatment and 16 (1.6%) were considered as conversion therapy. The main indication for treatment was: T4b lesions (n = 10), lymph node metastasis (n = 4), peritoneal carcinomatosis and hepatic metastasis in one case each. The diagnosis was made by imaging in 14 cases (75%) and during surgical procedure in four (25%). The most commonly used chemotherapy regimens were XP and mFLOX. Major surgical complications occurred in four cases (25%) and one (6.3%) died. After an average follow-up of 20 months, 11 patients (68.7%) had recurrence and nine (56.3%) died. Prolonged recurrence-free survival over 40 months occurred in two cases. Conclusion: Conversion therapy may offer the possibility of prolonged survival for a group of GC patients initially considered beyond therapeutic possibility.eng
dc.language.isoeng
dc.publisherCOLEGIO BRASILEIRO CIRURGIA DIGESTIVA-CBCDeng
dc.relation.ispartofAbcd-Arquivos Brasileiros de Cirurgia Digestiva-brazilian Archives of Digestive Surgery
dc.rightsopenAccesseng
dc.subjectStomach neoplasmseng
dc.subjectNeoadjuvant therapyeng
dc.subjectGastrectomyeng
dc.subject.otherlong-term survivaleng
dc.subject.otherphase-iieng
dc.subject.otherintraperitoneal paclitaxeleng
dc.subject.otherchemotherapyeng
dc.subject.otheresophagealeng
dc.subject.othersurgeryeng
dc.subject.othercisplatineng
dc.subject.otherconsensuseng
dc.subject.otherproposaleng
dc.titleCONVERSION THERAPY FOR GASTRIC CANCER: EXPANDING THE TREATMENT POSSIBILITIESeng
dc.typearticleeng
dc.rights.holderCopyright COLEGIO BRASILEIRO CIRURGIA DIGESTIVA-CBCDeng
dc.identifier.doi10.1590/0102-672020190001e1435
dc.identifier.pmid31038560
dc.subject.wosGastroenterology & Hepatologyeng
dc.type.categoryoriginal articleeng
dc.type.versionpublishedVersioneng
hcfmusp.description.articlenumberUNSP e1435
hcfmusp.description.issue2
hcfmusp.description.volume32
hcfmusp.origemWOS
hcfmusp.origem.idWOS:000482675300005
hcfmusp.origem.id2-s2.0-85065466304
hcfmusp.origem.idSCIELO:S0102-67202019000200304
hcfmusp.publisher.citySAO PAULO SPeng
hcfmusp.publisher.countryBRAZILeng
hcfmusp.relation.referenceBadgwell B, 2017, ANN SURG ONCOL, V24, P3338, DOI 10.1245/s10434-017-6047-4eng
hcfmusp.relation.referenceBang YJ, 2010, LANCET, V376, P1302eng
hcfmusp.relation.referenceChan DYS, 2017, J GASTROINTEST SURG, V21, P425, DOI 10.1007/s11605-016-3336-3eng
hcfmusp.relation.referenceCHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8eng
hcfmusp.relation.referenceCunningham D, 2008, NEW ENGL J MED, V358, P36, DOI 10.1056/NEJMoa073149eng
hcfmusp.relation.referenceDindo D, 2004, ANN SURG, V240, P205, DOI 10.1097/01.sla.0000133083.54934.aeeng
hcfmusp.relation.referenceDoyle DJ, 2017, AM SOC ANESTHESIOLOGeng
hcfmusp.relation.referenceEinama T, 2017, MOL CLIN ONCOL, V6, P163, DOI 10.3892/mco.2017.1128eng
hcfmusp.relation.referenceEnzinger PC, 2016, J CLIN ONCOL, V34, P2736, DOI 10.1200/JCO.2015.65.5092eng
hcfmusp.relation.referenceFerlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210eng
hcfmusp.relation.referenceFujitani K, 2016, LANCET ONCOL, V17, P309, DOI 10.1016/S1470-2045(15)00553-7eng
hcfmusp.relation.referenceFukuchi M, 2015, ANN SURG ONCOL, V22, P3618, DOI 10.1245/s10434-015-4422-6eng
hcfmusp.relation.referenceHartgrink HH, 2002, BRIT J SURG, V89, P1438, DOI 10.1046/j.1365-2168.2002.02220.xeng
hcfmusp.relation.referenceIlson DH, 1999, J CLIN ONCOL, V17, P3270, DOI 10.1200/JCO.1999.17.10.3270eng
hcfmusp.relation.referenceIsaji S, 2018, PANCREATOLOGY, V18, P2, DOI 10.1016/j.pan.2017.11.011eng
hcfmusp.relation.referenceIshigami H, 2010, ANN ONCOL, V21, P67, DOI 10.1093/annonc/mdp260eng
hcfmusp.relation.referenceJapanese Gastric Canc Assoc, 2017, GASTRIC CANCER, V20, P1, DOI 10.1007/s10120-016-0622-4eng
hcfmusp.relation.referenceKinoshita Hideki, 2005, JARE Data Reports, P1eng
hcfmusp.relation.referenceRamos MFKP, 2018, INT J SURG, V53, P366, DOI 10.1016/j.ijsu.2018.03.082eng
hcfmusp.relation.referenceMorgagni P, 2018, INT J SURG, V53, P360, DOI 10.1016/j.ijsu.2018.04.016eng
hcfmusp.relation.referenceNakamura T, 2004, AM J SURG, V188, P261, DOI 10.1016/j.amjsurg.2004.06.003eng
hcfmusp.relation.referencePereira MA, 2017, ABCD-ARQ BRAS CIR DI, V30, P30, DOI 10.1590/0102-6720201700010009eng
hcfmusp.relation.referenceVan Cutsem E, 2006, J CLIN ONCOL, V24, P4991, DOI 10.1200/JCO.2006.06.8429eng
hcfmusp.relation.referenceWashington K, 2010, ANN SURG ONCOL, V17, P3077, DOI 10.1245/s10434-010-1362-zeng
hcfmusp.relation.referenceYamaguchi K, 2018, GASTRIC CANCER, V21, P315, DOI 10.1007/s10120-017-0738-1eng
hcfmusp.relation.referenceYoshida K, 2016, GASTRIC CANCER, V19, P329, DOI 10.1007/s10120-015-0575-zeng
hcfmusp.relation.referenceZilberstein B, 2013, ABCD-ARQ BRAS CIR DI, V26, P2, DOI 10.1590/S0102-67202013000100002eng
dc.description.indexMEDLINEeng
dc.identifier.eissn2317-6326
hcfmusp.citation.scopus13-
hcfmusp.scopus.lastupdate2022-06-10-
Appears in Collections:

Artigos e Materiais de Revistas Científicas - FM/MGT
Departamento de Gastroenterologia - FM/MGT

Artigos e Materiais de Revistas Científicas - HC/ICESP
Instituto do Câncer do Estado de São Paulo - HC/ICESP

Artigos e Materiais de Revistas Científicas - HC/ICHC
Instituto Central - HC/ICHC

Artigos e Materiais de Revistas Científicas - LIM/24
LIM/24 - Laboratório de Oncologia Experimental

Artigos e Materiais de Revistas Científicas - LIM/35
LIM/35 - Laboratório de Nutrição e Cirurgia Metabólica do Aparelho Digestivo

Artigos e Materiais de Revistas Científicas - ODS/03
ODS/03 - Saúde e bem-estar


Files in This Item:
File Description SizeFormat 
art_RAMOS_CONVERSION_THERAPY_FOR_GASTRIC_CANCER_EXPANDING_THE_TREATMENT_2019.PDFpublishedVersion (English)500.86 kBAdobe PDFThumbnail
View/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.